191 related articles for article (PubMed ID: 34760925)
1. Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma.
Fan Y; Shan Q; Gong J; Qin J; Lu H
Front Mol Biosci; 2021; 8():736940. PubMed ID: 34760925
[No Abstract] [Full Text] [Related]
2. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
Zhao H; Chen J
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
[TBL] [Abstract][Full Text] [Related]
3. Primary pulmonary lymphoepithelioma-like carcinoma.
Fan Y; Li C; Qin J; Lu H
Med Oncol; 2020 Mar; 37(3):20. PubMed ID: 32146584
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma.
Wu Z; Xian X; Wang K; Cheng D; Li W; Chen B
Front Oncol; 2021; 11():626566. PubMed ID: 33981599
[TBL] [Abstract][Full Text] [Related]
5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
6. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics and cancer-specific prognosis of primary pulmonary lymphoepithelioma-like carcinoma: a population study of the US SEER database and a Chinese hospital.
Zhang Q; Dai Y; Jin L; Shi S; Liu C; Rong R; Sun W; Dai S; Kong H; Xie W
Front Oncol; 2023; 13():1103169. PubMed ID: 37274245
[TBL] [Abstract][Full Text] [Related]
8. Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden.
Wu Q; Wang W; Zhou P; Fu Y; Zhang Y; Shao YW; Jiang L
Pathol Res Pract; 2020 Aug; 216(8):153043. PubMed ID: 32703503
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis.
Tang L; Chen N; He W; Zhou J; Zhang J; Lin Z; Wang Z; Hao J; Lin F
PLoS One; 2020; 15(10):e0240729. PubMed ID: 33064745
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic profiling and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the stomach and parotid gland.
Cui Q; Wu H; Zeng W; Du H; Xiao Z; Hou T; Li M; Li Y; Zhang Z; Li Z
Ann Transl Med; 2022 Jan; 10(1):13. PubMed ID: 35242858
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
[TBL] [Abstract][Full Text] [Related]
12. Analysis of clinical features, treatment, and prognosis of primary Xlymphoepithelioma-like carcinoma of the lung.
Hu HY; Long L; Dai SA; Yan GQ; Huang Y; He J
Eur Rev Med Pharmacol Sci; 2022 Dec; 26(24):9416-9425. PubMed ID: 36591850
[TBL] [Abstract][Full Text] [Related]
13. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
Zhao D; Mambetsariev I; Li H; Chen C; Fricke J; Fann P; Kulkarni P; Xing Y; Lee PP; Bild A; Massarelli E; Koczywas M; Reckamp K; Salgia R
Lung Cancer; 2020 Aug; 146():174-181. PubMed ID: 32554069
[TBL] [Abstract][Full Text] [Related]
14. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
Dudnik E; Bshara E; Grubstein A; Fridel L; Shochat T; Roisman LC; Ilouze M; Rozenblum AB; Geva S; Zer A; Rotem O; Allen AM; Peled N
Lung Cancer; 2018 Oct; 124():117-124. PubMed ID: 30268448
[TBL] [Abstract][Full Text] [Related]
15. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
16. The relationship between different subtypes of
Yang Y; Shen S; Sun Y; Husain H; Zhou H; Lu S; Li Z
Transl Lung Cancer Res; 2022 Feb; 11(2):213-223. PubMed ID: 35280306
[TBL] [Abstract][Full Text] [Related]
17. Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma.
Jiang L; Wang L; Li PF; Zhang XK; Chen JW; Qiu HJ; Wu XD; Zhang B
Onco Targets Ther; 2015; 8():1451-7. PubMed ID: 26109869
[TBL] [Abstract][Full Text] [Related]
18. Development of a haematological indices-based nomogram for prognostic prediction and immunotherapy response assessment in primary pulmonary lymphoepithelioma-like carcinoma patients.
Sheng H; He X; Chen Z; Huang K; Yang J; Wei X; Mao M
Transl Lung Cancer Res; 2024 Mar; 13(3):453-464. PubMed ID: 38601436
[TBL] [Abstract][Full Text] [Related]
19. Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients.
Zhang J; Tang S; Zhang C; Li M; Zheng Y; Hu X; Huang M; Cheng X
Front Oncol; 2021; 11():742833. PubMed ID: 35087742
[TBL] [Abstract][Full Text] [Related]
20. Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review.
Archwamety A; Ruangchira-Urai R; Akewanlop C; Korphaisarn K
Thorac Cancer; 2022 Sep; 13(17):2539-2541. PubMed ID: 35830974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
